Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture

被引:66
作者
Fröhlich, E [1 ]
Machicao, F [1 ]
Wahl, R [1 ]
机构
[1] Med Clin, Dept Endocrinol Metab Nephrol & Pathobiochem, D-72076 Tubingen, Germany
关键词
D O I
10.1677/erc.1.00973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Differentiating drugs may be able to re-sensitize thyroid carcinomas to radioiodine therapy. Substituted thiazolidinediones (TZDs) belong to the group of oral anti-diabetic drugs that also possess anti-proliferative and pro-apoptotic effects and, potentially, differentiating effects on several cancer cell lines. Some of the effects are mediated via the peroxisome proliferator-activated receptor gamma (PPAR-gamma). We investigated the effect of troglitazone, rosiglitazone and pioglitazone on differentiation in normal porcine thyrocytes and in the follicular carcinoma cell lines FTC 133 and FTC 238. Differentiation was investigated by measuring I-125 uptake and the expression of sodium-iodide symporter and thyroglobulin proteins. The TZDs were tested in the presence of retinol and retinoic acid. Additionally, proliferation was evaluated by [H-3]thymidine uptake and cell number and apoptosis by annexin V-labeling. Controls included tocopherol and unsubstituted thiazolidinedione and co-incubation of the TZDs with the PPAR-gamma antagonist GW9662. PPAR-gamma and retinol X receptor (RXR)-alpha were investigated by immunocytochemistry, Western blot and RT-PCR. Cells derived from the metastasis showed greater responses than cells derived from the primary tumor. Troglitazone showed greater effects than the other TZDs. Troglitazone significantly increased I-125 uptake and apoptosis and decreased [H-3]thymidine uptake and cell number. The amount of the sodium iodide-symporter in the membrane fraction was significantly increased, while that of thyroglobulin was not influenced by the treatment. Inclusion of antagonist did not abolish these effects. No synergistic effect with any retinoid was detected. All transformed cells expressed PPAR-gamma and RXR-alpha but TZDs did not change their expression. Troglitazone appears to be suited for the re-differentiation treatment of dedifferentiated thyroid carcinoma because its action is twofold. On the one hand it increases differentiation and on the other hand it inhibits proliferation.
引用
收藏
页码:291 / 303
页数:13
相关论文
共 61 条
  • [1] Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apopiosis in human and rat hepatoma cell lines
    Bae, MA
    Rhee, H
    Song, BJ
    [J]. TOXICOLOGY LETTERS, 2003, 139 (01) : 67 - 75
  • [2] Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways
    Berge, K
    Tronstad, KJ
    Flindt, EN
    Rasmussen, TH
    Madsen, L
    Kristiansen, K
    Berge, RK
    [J]. CARCINOGENESIS, 2001, 22 (11) : 1747 - 1755
  • [3] Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
    Burstein, HJ
    Demetri, GD
    Mueller, E
    Sarraf, P
    Spiegelman, BM
    Winer, EP
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) : 391 - 397
  • [4] Gamma (γ) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (γ) expression in SW 480 human colon cancer cell lines -: art. no. 25
    Campbell, SE
    Stone, WL
    Whaley, SG
    Qui, M
    Krishnan, K
    [J]. BMC CANCER, 2003, 3 (1)
  • [5] 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells
    Clay, CE
    Monjazeb, A
    Thorburn, J
    Chilton, FH
    High, KP
    [J]. JOURNAL OF LIPID RESEARCH, 2002, 43 (11) : 1818 - 1828
  • [6] A phase II trial with rosiglitazone in liposarcoma patients
    Debrock, G
    Vanhentenrijk, V
    Sciot, R
    Debiec-Rychter, M
    Oyen, R
    Van Oosterom, A
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (08) : 1409 - 1412
  • [7] RETINOIC ACID-INDUCED DECREASE OF DNA-SYNTHESIS AND PEROXIDASE MESSENGER-RNA LEVELS IN HUMAN THYROID-CELLS EXPRESSING RETINOIC ACID RECEPTOR-ALPHA
    DELSENNO, L
    ROSSI, R
    GANDINI, D
    PIVA, R
    FRANCESCHETTI, P
    UBERTI, EC
    [J]. LIFE SCIENCES, 1993, 53 (13) : 1039 - 1048
  • [8] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
    Demetri, GD
    Fletcher, CDM
    Mueller, E
    Sarraf, P
    Naujoks, R
    Campbell, N
    Spiegelman, BM
    Singer, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) : 3951 - 3956
  • [9] Desmond JC, 2003, CANCER RES, V63, P505
  • [10] Elnemr A, 2000, INT J ONCOL, V17, P1157